Thermography in assessing treatment response to Golimumab in PsA
Research type
Research Study
Full title
A pilot study to evaluate the utility of thermography in assessing response to Golimumab treatment in Psoriatic Arthritis (Go-Thermal)
IRAS ID
193330
Contact name
Sonya Abraham
Contact email
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Psoriatic arthritis is a joint problem (arthritis) that often occurs with a skin condition called psoriasis. Psoriasis is a common skin problem that causes red patches on the body, and it is an on-going (chronic) inflammatory condition. About 1 in 20 people with psoriasis will develop arthritis with the skin condition. In most cases, psoriasis comes before the arthritis. The cause of psoriatic arthritis is not known.
Psoriatic arthritis can be treated using different types of drugs to reduce pain and swelling of the joints. New medicines that block an inflammatory protein called tumor necrosis factor (TNF) are being widely used for progressive psoriatic arthritis, as is the case of the drug Golimumab.
Thermography is the use of images to study heat distribution in different parts of the body, and allows one to see variations in temperature, for example in detecting joint inflammation.
This is a pilot study to evaluate whether Thermography is able to reliably detect joint inflammation in Psoriatic arthritis, and whether it is able to detect improvement or worsening in inflammation during medical treatment with Golimumab. This involves assessing disease activity using some questionnaires, examining of patient joints, performing blood tests, ultrasound and thermography.REC name
London - Harrow Research Ethics Committee
REC reference
16/LO/0415
Date of REC Opinion
25 Apr 2016
REC opinion
Further Information Favourable Opinion